Fermentalg (FALG) H1 2026 TU earnings summary

Executive summary

• Revenue for H1 2026 reached €7.4 million, nearly matching H1 2025, with a shift toward higher value-added segments.

• Significant growth in sales of the ORIGINSTM lipid range for dietary supplements and infant nutrition.

• First commercial order received for Galdieria Blue™, a natural blue dye, marking expansion into a new product platform.

Financial highlights

• H1 2026 revenue: €7.4 million, compared to €7.6 million in H1 2025.

• Nearly 20% growth in high value-added lipid segment sales, reaching close to €7 million.

• Strategic reduction in aquaculture sales (down 85% year-over-year), with renewed opportunities due to rising fish oil prices.

Outlook and guidance

• Anticipates strong acceleration in revenue growth in H2 2026, targeting €20 million in annual revenue.

• Ramp-up of industrial-scale production of Galdieria Blue™ planned for fall 2026.

• Commercialization of EPA/DHA combination to replicate fish oil composition expected to drive further growth.